Literature DB >> 28242493

C. elegans as a model system to accelerate discovery for Parkinson disease.

Bryan A Martinez1, Kim A Caldwell1, Guy A Caldwell2.   

Abstract

The nematode Caenorhabditis elegans possesses a wealth of opportunities to explore mechanisms which regulate metazoan complexity, basic cellular biology, and neuronal system attributes. Together, these provide a basis for tenable understanding of neurodegenerative disorders such as Parkinson disease (PD) through functional genomic analysis and pharmacological manipulation for the discovery of previously unknown genetic and environmental risk factors. The application of C. elegans has proven prescient in terms of the elucidation of functional effectors of cellular mechanisms underlying PD that translate to mammals. The current state of PD research using C. elegans encompasses defining obscure combinatorial interactions between genes or between genes and the environment, and continues to provide opportunities for the discovery of new therapeutic targets and disease-modifying drugs.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28242493     DOI: 10.1016/j.gde.2017.02.011

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  19 in total

1.  Distinct functional roles of Vps41-mediated neuroprotection in Alzheimer's and Parkinson's disease models of neurodegeneration.

Authors:  Edward F Griffin; Xiaohui Yan; Kim A Caldwell; Guy A Caldwell
Journal:  Hum Mol Genet       Date:  2018-12-15       Impact factor: 6.150

2.  N-Methyl-4-phenylpyridinium Scaffold-Containing Lipophilic Compounds Are Potent Complex I Inhibitors and Selective Dopaminergic Toxins.

Authors:  Bryan Lickteig; Virangika K Wimalasena; Kandatege Wimalasena
Journal:  ACS Chem Neurosci       Date:  2019-04-10       Impact factor: 4.418

Review 3.  Parkinson's disease and microRNAs - Lessons from model organisms and human studies.

Authors:  Brian Evans; Howard A Furlong; Alexandre de Lencastre
Journal:  Exp Gerontol       Date:  2021-10-08       Impact factor: 4.032

4.  Dual monoamine oxidase B and acetylcholine esterase inhibitors for treating movement and cognition deficits in a C. elegans model of Parkinson's disease.

Authors:  Jacob Boos; Ahmed Shubbar; Werner J Geldenhuys
Journal:  Med Chem Res       Date:  2021-04-09       Impact factor: 2.351

5.  Wedelolactone Mitigates Parkinsonism Via Alleviating Oxidative Stress and Mitochondrial Dysfunction Through NRF2/SKN-1.

Authors:  Shruti Sharma; Shalini Trivedi; Taruna Pandey; Sachin Ranjan; Mashu Trivedi; Rakesh Pandey
Journal:  Mol Neurobiol       Date:  2020-09-07       Impact factor: 5.590

6.  Caenorhabditis elegans Model Studies Show MPP+ Is a Simple Member of a Large Group of Related Potent Dopaminergic Toxins.

Authors:  David Murphy; Harshil Patel; Kandatege Wimalasena
Journal:  Chem Res Toxicol       Date:  2021-01-26       Impact factor: 3.739

7.  Virulence test using nematodes to prescreen Nocardia species capable of inducing neurodegeneration and behavioral disorders.

Authors:  Claire Bernardin Souibgui; Anthony Zoropogui; Jeremy Voisin; Sebastien Ribun; Valentin Vasselon; Petar Pujic; Veronica Rodriguez-Nava; Patrick Belly; Benoit Cournoyer; Didier Blaha
Journal:  PeerJ       Date:  2017-10-10       Impact factor: 2.984

8.  Neurotoxin-Induced Animal Models of Parkinson Disease: Pathogenic Mechanism and Assessment.

Authors:  Xian-Si Zeng; Wen-Shuo Geng; Jin-Jing Jia
Journal:  ASN Neuro       Date:  2018 Jan-Dec       Impact factor: 4.146

9.  Maackiain Ameliorates 6-Hydroxydopamine and SNCA Pathologies by Modulating the PINK1/Parkin Pathway in Models of Parkinson's Disease in Caenorhabditis elegans and the SH-SY5Y Cell Line.

Authors:  Rong-Tzong Tsai; Chia-Wen Tsai; Shih-Ping Liu; Jia-Xin Gao; Yun-Hua Kuo; Pei-Min Chao; Huey-Shan Hung; Woei-Cherng Shyu; Shinn-Zong Lin; Ru-Huei Fu
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

10.  Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening.

Authors:  Yukimoto Tsuda; Kunitoshi Yamanaka; Risa Toyoshima; Mitsuharu Ueda; Teruaki Masuda; Yohei Misumi; Teru Ogura; Yukio Ando
Journal:  Sci Rep       Date:  2018-12-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.